New drug targets Hard-to-Treat cancers in major trial

NCT ID NCT06660654

Ongoing Disease control Sponsor: Daiichi Sankyo Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called raludotatug deruxtecan (R-DXd) in 200 adults with advanced or spreading solid tumors, including certain ovarian, cervical, endometrial, bladder, and kidney cancers. The goal is to see if the drug can shrink tumors or stop them from growing. Participants must have tumors that have gotten worse after prior treatment. This is not a cure, but aims to control the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cervical cancer endometrial cancer metastatic malignant neoplasm nonpapillary renal cell carcinoma urothelial carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR METASTATIC SOLID TUMORS

Contacts and locations

Locations

AO per lEmergenza Cannizzaro

Catania, 95126, Italy
Aichi Cancer Centre

Nagoya, 464-8681, Japan
Asan Medical Center

Seoul, 05505, South Korea
Astera Cancer Care

East Brunswick, New Jersey, 08816, United States
Azienda Ospedaliera S Maria

Terni, 05100, Italy
Cario - Centre Armoricain de Radiothérapie, Imagerie Médicale Et Oncologie

Plérin, 22190, France
Centre Georges-François Leclerc

Dijon, 21079, France
Centre Leon Berard

Lyon, 69008, France
Centre Oscar Lambret

Lille, 59 000, France
Clinical Research Alliance

Westbury, New York, 11590, United States
Federico II Hospital

Naples, 80131, Italy
Fondazione IRCCS Istituto Nazionale dei Tumori

Milan, 40121, Italy
François Baclesse Center

Caen, 14000, France
Grp Hsp Diac Croix Saint Simon

Paris, 75012, France
Gustave Roussy

Villejuif, 94800, France
Herlev og Gentofte Hosp

Copenhagen, 2100, Denmark
Hospital 12 Octubre

Madrid, 28041, Spain
Hospital Universitario Virgen de la Victoria

Málaga, 29010, Spain
Hospital Universitario de A Coruña

A Coruña, 15006, Spain
Hospital de Sant Pau

Barcelona, 08041, Spain
Hunan Cancer Hospital

Changsha, 410013, China
Hyogo Cancer Center

Akashi, 13-70, Japan
IRCCS Dino Amadori - IRST

Meldola, 47014, Italy
IRCCS San Raffaele

Milan, 20132, Italy
Ico - Site René Gauducheau

Saint-Herblain, 44805, France
Institut Claudius Regaud

Toulouse, 31100, France
Irccs Ospedale San Martino

Genova, 16132, Italy
Md Anderson Cancer Centre

Madrid, 28033, Spain
Memorial Sloan-Kettering Cancer Center

New York, New York, 10065, United States
National Cancer Center

Goyang-si, 10408, South Korea
National Cancer Center Hospital

Chūōku, 104-0045, Japan
National Cancer Center Hospital East

Kashiwa, 277-8577, Japan
National Hospital Organization Kyushu Cancer Center

Fukuoka, 811-1395, Japan
Northside Hospital

Marietta, Georgia, 30060, United States
Osaka International Cancer Institute

Osaka, 541-8567, Japan
Saitama Medical University International Medical Center

Hidaka, 1397-1, Japan
Samsung Medical Center

Seoul, 06351, South Korea
Severance Hospital

Seoul, 03722, South Korea
Shanghai Cancer center

Shanghai, 200000, China
The Cancer Institute Hospital of Jfcr

Kōtoku, Japan
The Clínica Universidad de Navarra Madrid

Madrid, 28027, Spain
The University of Texas MD Anderson Cancer Center

Houston, Texas, 77030, United States
UZ Leuven Gynaec onco

Leuven, 3000, Belgium
University of Michigan Comprehensive Cancer Center Michigan Medicine

Ann Arbor, Michigan, 48109, United States
Vall d'Hebron University Hospital

Barcelona, 08035, Spain
West Cancer Center and Research Institute

Germantown, Tennessee, 38138, United States
Women's Cancer Care Associates

Albany, New York, 12208, United States
ZAS Sint-Augustinus

Wilrijk, 2610, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.